Anixa Biosciences (NASDAQ:ANIX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a $7.00 price target on the stock. HC Wainwright also issued estimates for Anixa Biosciences’ FY2024 earnings at ($0.42) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.46) EPS.

Separately, EF Hutton Acquisition Co. I raised shares of Anixa Biosciences to a strong-buy rating in a research note on Wednesday, August 7th.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $3.48 on Tuesday. The firm’s fifty day moving average is $3.18 and its 200-day moving average is $2.99. Anixa Biosciences has a 52 week low of $2.14 and a 52 week high of $5.13. The firm has a market cap of $111.38 million, a P/E ratio of -9.22 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Friday, September 6th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. As a group, sell-side analysts anticipate that Anixa Biosciences will post -0.43 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Lewis H. Titterton, Jr. bought 21,646 shares of the business’s stock in a transaction that occurred on Tuesday, July 30th. The shares were acquired at an average cost of $3.06 per share, with a total value of $66,236.76. Following the completion of the purchase, the director now directly owns 890,754 shares in the company, valued at $2,725,707.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Concorde Asset Management LLC bought a new position in shares of Anixa Biosciences in the second quarter valued at $31,000. Staley Capital Advisers Inc. bought a new position in shares of Anixa Biosciences in the first quarter valued at $31,000. Simplicity Wealth LLC bought a new position in shares of Anixa Biosciences in the first quarter valued at $44,000. Nations Financial Group Inc. IA ADV lifted its stake in shares of Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after buying an additional 7,500 shares in the last quarter. Finally, Virtu Financial LLC lifted its stake in shares of Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after buying an additional 5,183 shares in the last quarter. 29.13% of the stock is owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.